iX Biopharma Past Earnings Performance
Past criteria checks 0/6
Key information
9.4%
Earnings growth rate
14.6%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 40.3% |
Return on equity | -125.3% |
Net Margin | -158.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow iX Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6 | -10 | 7 | 2 |
30 Sep 23 | 6 | -10 | 8 | 2 |
30 Jun 23 | 6 | -10 | 9 | 3 |
31 Mar 23 | 5 | -13 | 9 | 3 |
31 Dec 22 | 4 | -16 | 9 | 3 |
30 Sep 22 | 9 | -10 | 9 | 3 |
30 Jun 22 | 14 | -5 | 9 | 2 |
31 Mar 22 | 14 | -3 | 10 | 2 |
31 Dec 21 | 14 | -2 | 10 | 3 |
30 Sep 21 | 8 | -5 | 9 | 3 |
30 Jun 21 | 2 | -8 | 8 | 3 |
31 Mar 21 | 2 | -8 | 8 | 3 |
31 Dec 20 | 2 | -8 | 8 | 3 |
30 Sep 20 | 1 | -9 | 8 | 2 |
30 Jun 20 | 1 | -10 | 8 | 2 |
31 Mar 20 | 1 | -12 | 8 | 3 |
31 Dec 19 | 1 | -12 | 8 | 3 |
30 Sep 19 | 1 | -13 | 8 | 3 |
30 Jun 19 | 1 | -13 | 8 | 4 |
31 Mar 19 | 1 | -14 | 8 | 6 |
31 Dec 18 | 0 | -16 | 8 | 7 |
30 Sep 18 | -1 | -15 | 7 | 8 |
30 Jun 18 | 0 | -15 | 7 | 8 |
31 Mar 18 | 2 | -14 | 8 | 6 |
31 Dec 17 | 3 | -13 | 8 | 6 |
30 Sep 17 | 7 | -10 | 8 | 6 |
30 Jun 17 | 6 | -7 | 8 | 5 |
31 Mar 17 | 6 | -4 | 7 | 5 |
31 Dec 16 | 6 | -4 | 7 | 5 |
30 Sep 16 | 6 | -6 | 6 | 6 |
30 Jun 16 | 6 | -8 | 7 | 6 |
31 Mar 16 | 6 | -11 | 6 | 5 |
31 Dec 15 | 7 | -11 | 6 | 5 |
30 Sep 15 | 7 | -11 | 6 | 5 |
30 Jun 15 | 7 | -11 | 6 | 5 |
31 Mar 15 | 6 | -8 | 5 | 3 |
31 Dec 14 | 5 | -6 | 4 | 3 |
30 Sep 14 | 3 | -4 | 3 | 2 |
30 Jun 14 | 2 | -3 | 2 | 1 |
30 Jun 13 | 0 | -2 | 0 | 1 |
Quality Earnings: 42C is currently unprofitable.
Growing Profit Margin: 42C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 42C is unprofitable, but has reduced losses over the past 5 years at a rate of 9.4% per year.